Search for: "In re: BIOLITEC INC"
Results 1 - 7
of 7
Sorted by Relevance
|
Sort by Date
4 Aug 2011, 7:40 am
Biolitec, Inc., 618 F.3d 1354, 1358-59 (Fed. [read post]
18 Aug 2017, 10:21 am
Biolitec, Inc., 618 F.3d 1354, 1358 (Fed. [read post]
27 Mar 2009, 7:20 am
(IP Watchdog) Legal studies program suspended (just_n_examiner) Books as prior art (just_n_examiner) Northern District of Illinois continues as top IP court – Administrative Office of the US Courts 2008 Annual Report (Chicago Intellectual Property Law Blog) Re-exam delays cause trouble for patent owners (Law360) Recovering pate [read post]
4 Oct 2010, 1:44 am
Int’l, Inc. v. [read post]
22 Nov 2011, 12:12 pm
Fletcher: As part of the Insured’s defense, the Defense policy automatically extends coverage to the cost of an invalidity defense to a charge of infringement, the cost of patent re-examination proceedings initiated as a defense arising out of a lawsuit for infringement and coverage for damages are available (IPISC covers damages back to the date the infringing activity began.) [read post]
28 Mar 2008, 6:00 am
: (IAM)DSS case: Europe’s patent demise: (IPEG),EU calls on US to fulfill TRIPS obligations re copyright: (The IP Factor),How to safeguard unprotected know-how in FP7 projects: (IPR Helpdesk),European Council calls for a free movement of knowledge: (IPR-Helpdesk),Madrid amendments for double-treatied Union members: (IPKat),Proposed Europe-wide rules governing biometric passports are still unsatisfactory despite some concessions, according to European Data Protection Supervisor:… [read post]
11 Jul 2008, 4:30 am
You can separately subscribe to the IP Thinktank Global week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: ACTA continues to be discussed and debated: (Michael Geist), (Intellectual Property Watch), (Public Knowledge), (Techdirt), (Managing Intellectual Property), (Public Knowledge), (Public Knowledge), (Public Knowledge), Apotex challenge to Acular LS patent barred by res judicata: Roche Palo Alto & Allergan v Apotex:… [read post]
